Pub. Date : 2021 Aug
PMID : 33768546
6 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | The haematocrit (HCT), postoperative time (POD) and CYP3A5*3 genotypes had a significant influence on TAC clearance when combined with WZC. | Tacrolimus | cytochrome P450 family 3 subfamily A member 5 | Homo sapiens |
| 2 | For patients carrying the CYP3A5*3/*3 allele and with 30% HCT, the required TAC dose to achieve target trough concentrations of 10-15 ng/ml was 4 mg twice daily (q12h). | Tacrolimus | cytochrome P450 family 3 subfamily A member 5 | Homo sapiens |
| 3 | For patients with the CYP3A5*3/*3 allele, the required dose was 3 mg TAC q12h when combined with WZC, and for patients with the CYP3A5*1/*1 or *1/*3 allele, the required dose was 4 mg of TAC q12h when co-administered with WZC. | Tacrolimus | cytochrome P450 family 3 subfamily A member 5 | Homo sapiens |
| 4 | For patients with the CYP3A5*3/*3 allele, the required dose was 3 mg TAC q12h when combined with WZC, and for patients with the CYP3A5*1/*1 or *1/*3 allele, the required dose was 4 mg of TAC q12h when co-administered with WZC. | Tacrolimus | cytochrome P450 family 3 subfamily A member 5 | Homo sapiens |
| 5 | WHAT IS NEW AND CONCLUSION: Wuzhi Capsule co-administration and CYP3A5 variants affect the PK of TAC Dosing guidelines are made based on the PPK model to allow individualized administration of TAC, especially when co-administered with WZC. | Tacrolimus | cytochrome P450 family 3 subfamily A member 5 | Homo sapiens |
| 6 | WHAT IS NEW AND CONCLUSION: Wuzhi Capsule co-administration and CYP3A5 variants affect the PK of TAC Dosing guidelines are made based on the PPK model to allow individualized administration of TAC, especially when co-administered with WZC. | Tacrolimus | cytochrome P450 family 3 subfamily A member 5 | Homo sapiens |